Medical device firms weigh Saudi distribution shifts

Medical device companies selling into Saudi Arabia’s healthcare market may need to rethink how much control they cede to local distributors, according to a new whitepaper from Eurogroup Consulting. The report argues that the Kingdom’s market has evolved beyond basic product distribution into what the authors call an “operating market”—one that demands a dedicated Saudi-specific strategy rather than management from a regional hub. This transformation reflects the growing complexity of procurement processes, where decisions are no longer driven solely by cost or product specifications but by a convergence of clinical, technical, and regulatory factors. The shift is particularly pronounced in the public healthcare sector, where centralized entities like NUPCO (the National Unified Procurement Company) now consolidate purchasing power, requiring manufacturers to align with both standardized tender processes and the evolving priorities of hospital clusters.

The whitepaper highlights that this evolution is less about market growth than about structural changes in how purchasing decisions are made. Clinicians, biomedical engineering teams, procurement departments, and centralized buyers now collaborate in evaluating suppliers, with local-content requirements enforced by the Local Content and Government Procurement Authority (LCGPA) adding another layer of complexity. Unlike in the past, where a single relationship or tender could secure a contract, today’s procurement setting demands a multi-faceted approach that balances clinical efficacy, technical compatibility, financial sustainability, and regulatory compliance. Jack Fowler, Principal at Eurogroup Consulting Middle East, said: “Saudi healthcare decisions are no longer won through one relationship or one tender. They are shaped across clinical, technical, procurement and financial priorities. Local partners remain essential, but without direct visibility into strategic accounts, manufacturers risk losing influence where growth is decided.”

This shift has pushed companies toward what the whitepaper calls a solution-centric approach, where hospitals evaluate suppliers not only on product quality but on their ability to enhance workflow efficiency, provide specialized training, integrate digital health solutions, and deliver measurable clinical or economic outcomes. The traditional distributor-only model—where partners handle registration, tenders, logistics, and account support—remains viable for certain product categories, particularly those with broad but non-critical applications or fragmented customer bases. However, for higher-value or strategically important products, this model presents recurring limitations, including:

Limited direct access to end users

Weak transparency on pricing and margins

Limited ability to defend strategic accounts

Slow response to market changes

Distributor instability or competing portfolio priorities

The whitepaper suggests a hybrid model as a middle ground, where manufacturers retain direct control over strategic accounts, tender strategy, pricing governance, clinical education, regulatory strategy, distributor governance, service standards, local-content strategy, and market and tender-pipeline intelligence. This approach ensures that critical commercial levers—such as market intelligence and tender pipeline visibility—remain under the manufacturer’s direct influence. Meanwhile, distributors continue to play a role in regulatory administration, importation and warehousing, routine tender administration, regional account coverage, training logistics, first-line maintenance and collections. This division of responsibilities allows companies to leverage local expertise where it is most efficient while preserving the ability to respond rapidly to market demands.

The report outlines a five-model spectrum for distributor arrangements, ranging from a traditional distributor-led approach to a strategic localization partner model, with the appropriate structure depending on scale, portfolio breadth and localisation ambitions. It notes that some global manufacturers—among them Siemens Healthcare, Philips Healthcare, Medtronic—have already adopted hybrid or direct models in Saudi Arabia.

Local content without full manufacturing

The whitepaper clarifies that Saudi Arabia’s local-content requirements do not mandate in-country manufacturing for every company. Instead, it proposes a five-phase roadmap to compliance, beginning with establishing a local commercial and tender presence and progressing through building service and training capabilities, setting up warehousing for spare parts, and repackaging or relabeling products. Only in the final phase—where justified by market demand and strategic necessity—does selective manufacturing or technology transfer become relevant. This phased approach allows companies to meet LCGPA expectations without prematurely committing to full-scale production, which may not be feasible or cost-effective for all manufacturers.

A regional headquarters (RHQ) is framed as a strategic option rather than a default requirement, particularly for companies with cross-country management functions or significant public-sector exposure. However, the report cautions that an RHQ should not replace local service quality or distributor governance. Instead, it should complement these efforts by providing centralized oversight where it enhances efficiency without compromising the ability to respond to localized market needs.

A structured decision framework

To help companies handle these choices, Eurogroup Consulting proposes evaluating their Saudi go-to-market strategy across five dimensions: market attractiveness, commercial control, partner model, local-content readiness, and organizational investment. This framework moves beyond broad strategic questions—such as “How should we operate in Saudi Arabia?”—toward specific decisions about where to retain control, where to partner, and how far to localize. By assessing these dimensions systematically, manufacturers can align their strategies with the market’s evolving demands, ensuring they neither over- nor under-invest in local operations.

Medical device companies entering or expanding in Saudi Arabia now face a more complex setting than in past years. The market’s evolution toward an operating model—driven by centralized procurement, clinical demands, and local-content rules—means distributors alone may no longer suffice. The whitepaper’s hybrid approach offers a middle path: leveraging local partners where efficient but keeping strategic levers in-house where growth depends on direct influence. The shift is not about abandoning distributors but redefining their role to better align with the market’s demands. For companies with broad portfolios or fragmented customer bases, the traditional model may still work, but for those targeting high-value products or strategic accounts, a more balanced approach could determine whether they gain or lose market access in the Kingdom’s increasingly competitive setting.

The report’s authors—Damien Duhamel (Managing Partner at Eurogroup Consulting Middle East), Jack Fowler (Principal), and Josephina Mallah (Senior Consultant)—emphasize that the key to success lies in recognizing the market’s structural changes and adapting accordingly. Eurogroup Consulting, an independent strategy and management consultancy with a global network of 3,000 consultants, has positioned itself as a guide for companies handling these transitions, offering tailored insights based on years of experience in the Middle East and Asia. For those seeking further details, the full whitepaper, “Own It or Outsource It? Finding a Smarter Way to Distribute Medical Devices in KSA,” is available [here](https://eurogroupconsultingmea.com/insights/whitepapers/saudi-arabia-s-medical-device-market-is-your-operating-model-ready).